MedTrace Logo

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

NCT02011321 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-02-01

No results posted yet for this study

Summary

Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm

Conditions

  • Subarachnoid Hemorrhage
  • Cerebral Aneurysm
  • Vasospasm, Intracranial

Interventions

DRUG

clevidipine

clevidipine infusion x4 hours

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Panayiots Varelas, MD, PhD · Henry Ford Health System

  • Tamer Abdelhak, MD · Henry Ford Health System

  • Mohammed Rehman, DO · Henry Ford Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2018-03-31
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02011321 on ClinicalTrials.gov